Table 1: Patients' demographics (A), cognitive assessment tests (B), and percent of patients on different classes of medication (C). The values are mean ± SD. P values ≤ 0.05 are statistically significant.
|
A-Demographics |
AD |
|
Pure AD |
MCI |
CTL |
P (AD/CTL) |
P (PAD/CTL) |
|
P (MCI/CTL) |
|
Sample size |
43 (30 M) |
15 (9 M) |
12 (8 M) |
21 (10 M) |
|
||||
|
|
|
||||||||
|
Age ± SD (Years) |
71.3 ± 11 |
70.8 ± 15 |
67.4 ± 7 |
70.4 ± 8 |
0.74 |
0.65 |
|
0.29 |
|
|
|
|
||||||||
|
% APOE4 (1 copy) |
67 |
53 |
58 |
28 |
0.002 |
0.09 |
|
0.02 |
|
|
B-Cognitive Assessment Tests |
|
|
|||||||
|
MMSE |
20.7 ± 6 |
22.7 ± 7 |
28.5 ± 1 |
29.4 ± 1.0 |
< 0.001 |
< 0.001 |
|
0.11 |
|
|
CDR |
0.85 ± 0.5 |
0.64 ± 0.5 |
0.18 ± 0.2 |
0.0 ± 0 |
< 0.001 |
< 0.001 |
|
0.009 |
|
|
CDR-SOB |
5.7 ± 3 |
4.2 ± 3 |
0.45 ± 0.8 |
0.0 ± 0 |
< 0.001 |
< 0.001 |
|
0.02 |
|
|
C-Medications (% of pts) |
|
|
|||||||
|
AchEIs |
81 |
|
---- |
|
|||||
|
Memantine |
18 |
|
---- |
|
|||||
|
Psychotropic drugs |
65 |
|
25 |
< 0.01 |
|
||||
|
Cardiovascular drugs |
82 |
|
85 |
> 0.05 |
|
Abbreviations: AchEI: Acetylcholinesterase inhibitor; AD: Alzheimer’s disease; APOE: Apolipoprotein E; CDR: Clinical dementia rating; CTL: Control; MCI: Mild cognitive impairment; MMSE: Mini mental state examination; PAD: Pure AD; SOB: Sum of boxes